Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03852472 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

A Phase 2 study, sponsored by Amgen.

Completed
Registry status
Phase 2
Development phase
435
Enrollment target

NCT03852472 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 435 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03852472, a Phase 2 study, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 2
Development phase
435 participants
Enrollment target

Study Summary

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Interventions

  • OTHER Placebo
  • DRUG Avacopan

Trial Details

FieldValue
Enrollment Target 435 participants
Start Date 2018-12-21
Est. Completion 2021-03-09
Phase Phase 2

Sponsor

Amgen

558 total trials

What the Registry Record Tells You About NCT03852472

The ClinicalTrials.gov registry entry for NCT03852472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03852472 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03852472 about?

NCT03852472 is a clinical study titled "Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)". Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

What is the current status of trial NCT03852472?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 435 participants. The study started on 2018-12-21. Estimated completion is 2021-03-09.

What interventions are being tested in trial NCT03852472?

The interventions under investigation include: Placebo (OTHER), Avacopan (DRUG).

Who is sponsoring clinical trial NCT03852472?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.